Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET

Company Participants

Brant Biehn - Senior Vice President, Business Operations

Andrei Floroiu - Chief Executive Officer

James Cummings - Chief Medical Officer

Sean Tucker - Founder & Chief Scientific Officer

Phil Lee - Chief Financial Officer

Conference Call Participants

Charles Duncan - Cantor Fitzgerald

Mayank Mamtani - B. Riley Securities

Operator

Greetings. Welcome to Vaxart Business Update and Full Year 2022 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors may submit written questions to ir@vaxart.com. As a reminder, this conference is being recorded.

I would now like to turn the webcast over to your host, Brant Biehn, Senior Vice President, Business Operations. Thank you. You may begin.

Brant Biehn

Good afternoon, and welcome to today's call. Joining us from Vaxart are Andrei Floroiu, our Chief Executive Officer; Dr. Sean Tucker, our Founder and Chief Science Officer; and Dr. James Cummings, our Chief Medical Officer; and Phil Lee, our Chief Financial Officer.

Before we get started, I’d like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, and other risks described in the Risk Factors section of Vaxart's most recently filed annual report on Form 10-K and other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call.

I'll now turn the call over to Andrei Floroiu. Andrei?

Andrei Floroiu

Thank you, Brant, and thanks to all of you joining us today. We are pleased to share with you our corporate strategy update and talk about how we'll be progressing our transformational oral vaccine platform.

As we said in the press release we issued this afternoon, we are prioritizing the development of our oral pill bivalent norovirus vaccine candidate, as we believe this to be the best strategy to position Vaxart for long-term success and maximize shareholder value.

Our goal of this strategy is to focus most of our investments on the programs that have the greatest near-term potential to validate and progress our oral pill technology platform. Norovirus represents a very attractive target for Vaxart, because of the very compelling risk-reward profile of our program.